NAGIOS: RODERIC FUNCIONANDO

Oral cancer: current role of radiotherapy and chemotherapy

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Oral cancer: current role of radiotherapy and chemotherapy

Mostra el registre parcial de l'element

dc.contributor.author Huang, Shao Hui es
dc.contributor.author O'Sullivan, Brian es
dc.date.accessioned 2014-05-29T07:04:56Z
dc.date.available 2014-05-29T07:04:56Z
dc.date.issued 2013 es
dc.identifier.citation Huang, Shao Hui ; O'Sullivan, Brian. Oral cancer: current role of radiotherapy and chemotherapy. En: Medicina oral, patología oral y cirugía bucal. Ed inglesa, 2013, Vol. 18, No. 2: 233-240 es
dc.identifier.uri http://hdl.handle.net/10550/35585
dc.description.abstract The term oral cavity cancer (OSCC) constitutes cancers of the mucosal surfaces of the lips, floor of mouth, oral tongue, buccal mucosa, lower and upper gingiva, hard palate and retromolar trigone. Treatment approaches for OSCC include single management with surgery, radiotherapy [external beam radiotherapy (EBRT) and/or brachy therapy], as well as adjuvant systemic therapy (chemotherapy and/or target agents); various combinations of these modalities may also be used depending on the disease presentation and pathological findings. The selection of sole or combined modality is based on various considerations that include disease control probability, the anticipated functional and cosmetic outcomes, tumor resectability, patient general condition, and availability of resources and expertise. For resectable OSCC, the mainstay of treatment is surgery, though same practitioners may advocate for the use of radiotherapy alone in selected "early" disease presentations or combined with chemotherapy in more locally advanced stage disease. In general, the latter is more commonly reserved for cases where surgery may be problematic. Thus, primary radiotherapy ± chemotherapy is usually reserved for patients unable to tolerate or who are otherwise unsuited for surgery. On the other hand, brachytherapy may be considered as a sole modality for early small primary tumor. It also has a role as an adjuvant to surgery in the setting of inadequate pathologically assessed resection margins, as does postoperative external beam radiotherapy ± chemotherapy, which is usually reserved for those with unfavorable pathological features. Brachytherapy can also be especially useful in the reirradiation setting for persistent or recurrent disease or for a second primary arising within a previous radiation field. Biological agents targeting the epithelial growth factor receptor (EGFR) have emerged as a potential modality in combination with radiotherapy or chemoradiotherpy and are currently under evaluation in clinical trials. en_US
dc.subject Odontología es
dc.subject Ciencias de la salud es
dc.title Oral cancer: current role of radiotherapy and chemotherapy es
dc.type journal article es_ES
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.type.hasVersion VoR es_ES

Visualització       (834.6Kb)

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques